Amalgamation/Merger

Filed: 04 Nov 2026, 20:25 IST Exchange: NSE Category: Merger/Acquisition — Subsidiary Amalgamation

Amalgamation of wholly owned subsidiaries Auroactive Pharma Pvt Ltd and Apitoria Pharma Pvt Ltd approved by boards. Auroactive Pharma turnover INR 701.3 mn, Apitoria Pharma INR 64,430.8 mn for FY26. Both engaged in API manufacturing. Merger aims to consolidate API businesses, improve operational efficiency, optimize capacity utilization, and simplify corporate structure. Share exchange ratio: 97 Apitoria shares per 10,000 Auroactive shares. No change in parent company shareholding.

Source: Original filing PDF — view on exchange portal

⚡ You're reading this after the fact — subscribers got it instantly

ISA

Indian Stock Alerts BOT

🚨 AUROPHARMA — Quarterly Results

Revenue: ₹2,35,800 Cr (+12% YoY)

PAT: ₹19,200 Cr (+17% YoY)

EBITDA margin: 16.8%

Board declared ₹10/share dividend. Jio adds 8M subs.

📎 bseindia.com/xml-data/...

🎧 Audio summary ready

✓✓ 6:47 PM

🎧

Instant audio summaries2-min AI concall recap delivered with every earnings alert

📊

20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings

🔍

Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically

⚡

Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add AUROPHARMA to your watchlist — all of this, automated.

14-day Pro trial · No credit card · Cancel anytime

More on Aurobindo Pharma Limited

Important. The summary above is generated automatically from Aurobindo Pharma Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.